Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model

Gene Therapy

Volumn 5, Issue 11, 1998, Pages 1447-1454

  Souberbielle, B E ^a,b,c   Westby, M ^a   Ganz, S ^a   Kayaga, J ^a   Mendes, R ^b,c   Morrow, Wjw ^d   Dalgleish, A G ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Allogenic tumour vaccination; B16 F10 melanoma; B7.1; Hybrid cells

Indexed keywords

ADJUVANT; ALLOANTIGEN; AUTOANTIGEN; PROVAX; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; DENDRITIC CELL; INTERMETHOD COMPARISON; MACROPHAGE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0031772473     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300747     Document Type: Article

References (38)

1. Speiser DE et al. Self antigens expressed by solid tumours do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J Exp Med 1997; 186: 645-653.
2. Chen L et al. Costimulation of antitumour immunity by the B7 counterreceptor for the T lymphocyte molecules CD 28 and CTLA-4. Cell 1992; 71: 1093-1102.
3. Hahne M et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumour immune escape. Science 1996; 274: 1363-1366.
4. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Prof Natl Acad Sci USA 1993; 90: 3539-3543.
5. Allione A et al. Immunizing and curative potential of nonreplicating marine mamary adenocarcinoma cells engineered with interleukin IL-2, IL-4, IL-6, IL-7, IL-10, tumour necrosis factor alpha, granulocyte-maerophage colony-stimulating factor and gamma Interferon gene or admixed with conventional adjuvant. Cancer Res 1995; 54: 6022-6026.
6. Schwartz RH. Costimulation of T lymphocyte: the role of CD28, CTLA-4 and B7/BB1 in interleukin 2 production and immunotherapy. Cell 1994; 71: 1065-1068.
7. Chong H, Hutchinson G, Hart IR, Vile RG. Expression of costimulatory molecules by tumour cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther 1996; 7: 1771-1779.
8. Souberbielle BE et al. Comparison of IL-2 and IL-4 transfected B16-F10 with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine. Gene Therapy 1996; 3: 853-858.
9. Knight BC et al. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996; 6: 299-306.
10. Toes RE et al. Protective antitumor immunity by immunization with completely allogeneic rumor cells. Cancer Res 1996; 56: 3782-3787.
11. Hearing VJ, Vieira WD, Law LW. Malignant melanoma: cross reacting (common) tumor rejection antigens. Int J Cancer 1985; 35: 403-409.
12. Huang AY et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
13. Maass G et al. Priming of rumor-specific T cells in the draining lymph nodes after immunization with IL-2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995; 92: 5540-5544.
14. Cayeux S et al. Influence of gene-modified (IL-7, IL-4 and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997; 158: 2834-2841.
15. Sheikh N, Rajananthanan P, Morrow WJW. Adjuvant-mediated antigen processing: how soluble protein enters the class I pathway. Immunology 1997; 92 (Suppl. 1): 59 (Abstr.).
16. Sheikh N, Rajananthanan P, Morrow WJW. Adjuvant-mediated antigen processing: a model for TAP independent processing. Immunology 1997; 92 (Suppl. 1): 59, (Abstr.).
17. Chen L et al. Tumour immunogenicity determines the effect of B7 costimulation on T cell-mediated tumour immunity. J Exp Med 1994; 179: 523-532.
18. Wu TC et al. A reassessment of the role of B7-1 in tumour rejection. J Exp Med 1995, 182: 1425-1421.
19. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo. J Exp Med 1996, 183: 769-776.
20. --mediated rejection of established tumour. Hum Gene Ther 1997; 8: 477-488.
21. Guo Y et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994; 263: 518-520.
22. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med 1997; 5: 558-561.
23. Delbrick JE, Campbell PA, Staerz UD. Macrophages as accessory cells for class I MHC-restricted immune response. J Immunol 1991; 147: 2846-2851.
24. + CTLs from naïve precursors. J Immunol 1994, 153: 996-1003.
25. Dunnion DJ, Cywinski A, Rickinson A, Browning MJ. Immunostimulatory tumour cell hybrids as potential candidates for cancer vaccines. Immunology 1997; 92 (Suppl. 1): 15.
26. Hart I, Colaco C. Fusion induces tumour rejection (news and views). Nature Med 1997; 388: 626-627.
27. Guo YJ et al. Effective tumor vaccines generated by in vitro modification of tumour cells with cytokines and bispecific monoclonal antibodies. Nature Med 1997; 3: 451-455.
28. Stuhler G, Walden P Recruitment of helper T cells induction of rumour rejection by cytolytic T lymphocytes. Cancer Immunol Immunother 1994; 39: 342-345.
29. Trefzer U et al. Phase I trial with a hybrid cell vaccine in patients with metastatic melanoma. Proc 3rd European Conference on Gene Therapy of Cancer. 1997, 182 (Abstr. D136).
30. Kugler A et al. Generation of hybrid cell vaccine for the treatment of patients with advanced renal cell carcinoma. Proc 3rd European Conference on Gene Therapy of Cancer. 1997, 183 (Abstr. D137).
31. 3, or C colon cancer. Proc ASCO 1996; 15: 444.
32. Fidler IJ, Kripke ML Metastasis results from pre-existing variant cells within a malignant tumor. Science 1977; 197: 893-895.
33. Fidler IJ et al. Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J Natl Cancer Inst 1981; 67: 947-956.
34. Wakeling WF, Greetham J, Devlin LM, Bennett DC. Suppression of properties associated with malignancy in murine melanomamelanocyte hybrid cells. Br J Cancer 1992; 65: 529-537.
35. Fortier AH. Isolation of murine macrophages. In: Coligan JE et al (eds). Current Protocols in Immunology. John Wiley: New York, 1994, pp 14.1.1-14.1.9.
36. Wakeling WF, Souberbielle BE, Bennett DC. Detection of a human DNA sequence correlated with melanocyte-like differentiation and tumour suppression after transfection into murine melanoma cells. Melanoma Res 1995; 5: 27-40.
37. Turpeennniemi-Hujanen T et al. Expression of collagenase IV (basement membrane collagenase) activity in murine rumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 1985; 75: 99-103.
38. Hariharan K et al. The induction of cytotoxic T cells and rumour regression by soluble antigen formulation. Cancer Res 1995; 55: 3486-3489.